CBD No Better Than Placebo for Cancer Symptoms, Study Finds

A study¹ published in the Journal of Clinical Oncology has raised new questions about the role of cannabidiol (CBD) in cancer care. Conducted by Mater Research in collaboration with the University of Queensland, the double-blind, placebo-controlled trial found that CBD offered no more symptom relief than placebo in patients with advanced cancer. This finding challenges assumptions about CBD’s effectiveness in palliative care and reignites the debate over how cannabinoids should be studied and prescribed.

Inside the Study

The trial included 144 participants receiving palliative treatment for late-stage cancer. Over 28 days, patients received either pure CBD or placebo, with titrations from 50 mg/day to 600 mg/day. Researchers measured improvements in pain, anxiety, depression, and overall distress, along with adverse events at days 14 and 28.

The results were striking: patients in both the CBD and placebo arms reported similar outcomes, with no significant differences in symptom improvement. Adverse effects were minimal and unrelated to either intervention. The researchers concluded: “CBD may not add value in reducing symptoms for patients with advanced cancer beyond standard palliative care.”

Dosage: Too Low or Just Ineffective?

Some observers argue that dosage could have played a role. For context, Epidiolex (a prescription CBD product for epilepsy) is administered at 5–20 mg/kg/day—equivalent to 350–1,400 mg daily for a 70 kg adult. By comparison, the upper dose in this cancer study capped at 600 mg/day, raising the possibility that higher doses might be needed to see an effect. Other research has shown benefit at 300 mg/day for conditions such as chemotherapy-induced neuropathy.

Still, it may not be as simple as “more CBD equals better results.” The reality is that CBD isolate may not be sufficient for the broad range of cancer symptoms when studied as a single compound.

CBD Isolate vs. Full Spectrum Extracts

The trial used pure CBD isolate, but many in the medical cannabis community point to the entourage effect—the synergistic interplay of cannabinoids and terpenes—as a more effective therapeutic pathway. For example, THC has proven analgesic and anti-nausea properties, while CBD may reduce THC’s adverse effects. Together, they may work better than either compound alone. This raises an important question: was CBD ever the right cannabinoid to test on its own for such a wide range of symptoms?

CBD Isolate vs. Full-Spectrum CBD for Cancer Symptoms

The Patient Perspective

Despite the trial’s findings, 36% of participants chose to continue purchasing CBD after the study ended. Researchers attribute this to patient optimism, but it’s also possible that some individuals genuinely experienced an improvement in wellbeing, even if not measurable within the trial’s parameters. As Dr. Peter Grinspoon has noted, “people almost exclusively talk about their quality of life getting better when using cannabis compared to opiates.”

So, Is CBD Effective for Cancer?

The answer remains complicated. Some laboratory studies suggest CBD has anti-tumor potential in specific cancers, while clinical trials like this one raise doubts about its symptomatic relief. One study cannot provide a definitive verdict, especially when different doses, delivery methods, and cannabinoid combinations remain unexplored.

The truth may lie somewhere between patient optimism and medical skepticism. While CBD isolate may not live up to the hype in advanced cancer care, whole-plant extracts and personalized cannabinoid medicine still hold promise. As with much of medical cannabis, the field requires more rigorous, condition-specific studies before sweeping conclusions can be drawn.

References:

^{1. Janet Hardy et al., Phase IIb Randomized, Placebo-Controlled, Dose-Escalating, Double-Blind Study of Cannabidiol Oil for the Relief of Symptoms in Advanced Cancer (MedCan1-CBD). JCO 41, 1444-1452(2023). DOI:10.1200/JCO.22.01632}